Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Dose Two Way Crossover Comparative Bioavailability Study of Lamotrigine Extended-Release Tablets USP 50 mg in Healthy Male and Female Volunteers Fasting State

NCT05145608 is registered in ClinicalTrials.gov with Alembic Pharmaceuticals Ltd. as lead sponsor.

NCT NCT05145608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05145608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Dose Two Way Crossover Comparative Bioavailability Study of Lamotrigine Extended-Release Tablets USP 50 mg in Healthy Male and Female Volunteers Fasting State
Lead sponsor
Alembic Pharmaceuticals Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 10, 2018
Completion date
February 21, 2018
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence